MedImmune Vaccines

Summary

Organization: MedImmune Vaccines
Country: USA

Top Publications

  1. pmc Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials
    Raburn M Mallory
    MedImmune, LLC, Gaithersburg, Maryland, United States of America
    PLoS ONE 5:e13755. 2010
  2. doi Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Gaithersburg, Maryland 20878, USA
    Arthritis Rheum 60:1785-96. 2009
  3. ncbi GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection
    Taff Jones
    MedImmune, Clinical Testing Laboratories, Mountain View, CA 94043, USA
    Curr Opin Mol Ther 11:337-45. 2009
  4. pmc Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza
    Christopher S Ambrose
    MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Influenza Other Respir Viruses 2:193-202. 2008
  5. doi Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay
    Yuling Wu
    Pharmacokinetics and Drug Metabolism, Amgen Inc, Thousand Oaks, CA 91320, USA
    J Pharm Biomed Anal 49:1203-12. 2009
  6. doi Test homogeneity of risk difference across subgroups in clinical trials
    Lanju Zhang
    Department of Biostatistics, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878, USA
    J Biopharm Stat 19:67-76. 2009
  7. pmc Gene-environment interactions in chronic obstructive pulmonary disease
    Nestor A Molfino
    MedImmune, Gaithersburg, MD 20878, USA
    Int J Chron Obstruct Pulmon Dis 3:491-7. 2008
  8. doi A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria
    Elissa Malkin
    PATH Malaria Vaccine Initiative, Bethesda, MD, USA
    Vaccine 26:6864-73. 2008
  9. pmc Type I interferon: potential therapeutic target for psoriasis?
    Yihong Yao
    MedImmune, Inc, Gaithersburg, Maryland, United States of America
    PLoS ONE 3:e2737. 2008
  10. doi A novel method for determination of the affinity of protein: protein interactions in homogeneous assays
    Philip Newton
    MedImmune Ltd Milstein Building, Granta Park, Cambridge, UK CB1 6GH
    J Biomol Screen 13:674-82. 2008

Detail Information

Publications62

  1. pmc Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials
    Raburn M Mallory
    MedImmune, LLC, Gaithersburg, Maryland, United States of America
    PLoS ONE 5:e13755. 2010
    ..The safety, tolerability, and immunogenicity of a monovalent intranasal 2009 A/H1N1 live attenuated influenza vaccine (LAIV) were evaluated in children and adults...
  2. doi Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
    Yihong Yao
    MedImmune, Gaithersburg, Maryland 20878, USA
    Arthritis Rheum 60:1785-96. 2009
    ..e., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-10 (IL-10), tumor necrosis factor alpha (TNFalpha), and IL-1beta, in SLE...
  3. ncbi GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection
    Taff Jones
    MedImmune, Clinical Testing Laboratories, Mountain View, CA 94043, USA
    Curr Opin Mol Ther 11:337-45. 2009
    ..With the enormous demand for an effective vaccine in the event of an H5N1 pandemic, GSK's inactivated split H5N1 virus vaccine likely will be a highly valued product...
  4. pmc Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza
    Christopher S Ambrose
    MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Influenza Other Respir Viruses 2:193-202. 2008
    ..Formulations of LAIV against pandemic influenza strains, including H5N1, H9N2, and H7N3, are currently being tested in preclinical and phase I clinical studies...
  5. doi Tartrate-resistant acid phosphatase (TRACP 5b): a biomarker of bone resorption rate in support of drug development: modification, validation and application of the BoneTRAP kit assay
    Yuling Wu
    Pharmacokinetics and Drug Metabolism, Amgen Inc, Thousand Oaks, CA 91320, USA
    J Pharm Biomed Anal 49:1203-12. 2009
    ..The method was robust with similar assay performance characteristics shown in three bioanalytical laboratories...
  6. doi Test homogeneity of risk difference across subgroups in clinical trials
    Lanju Zhang
    Department of Biostatistics, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878, USA
    J Biopharm Stat 19:67-76. 2009
    ..Results show that one of our new methods has a type I error rate that is closest to the nominal level among all the methods and is much more powerful than those proposed by Lipsitz et al...
  7. pmc Gene-environment interactions in chronic obstructive pulmonary disease
    Nestor A Molfino
    MedImmune, Gaithersburg, MD 20878, USA
    Int J Chron Obstruct Pulmon Dis 3:491-7. 2008
    ..It is anticipated that an improved understanding of this interaction will both enable improved identification of individuals susceptible to developing this disease, as well as improved future treatments for this disease...
  8. doi A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria
    Elissa Malkin
    PATH Malaria Vaccine Initiative, Bethesda, MD, USA
    Vaccine 26:6864-73. 2008
    ..At all three dose levels and both schedules, this formulation of PfCP2.9/ISA 720 is well tolerated, safe and immunogenic; however no functional activity against the parasite was observed...
  9. pmc Type I interferon: potential therapeutic target for psoriasis?
    Yihong Yao
    MedImmune, Inc, Gaithersburg, Maryland, United States of America
    PLoS ONE 3:e2737. 2008
    ..To better understand the pathogenesis of this disease and identify potential mediators, we used whole genome array analysis to profile paired lesional and nonlesional psoriatic skin and skin from healthy donors...
  10. doi A novel method for determination of the affinity of protein: protein interactions in homogeneous assays
    Philip Newton
    MedImmune Ltd Milstein Building, Granta Park, Cambridge, UK CB1 6GH
    J Biomol Screen 13:674-82. 2008
    ..The advantages and limitations of the method are discussed...
  11. doi Duration of protection provided by live attenuated influenza vaccine in children
    Christopher S Ambrose
    MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Pediatr Infect Dis J 27:744-8. 2008
    ..Reliable availability of influenza vaccine before October could enable the vaccination of many children who might not otherwise be vaccinated...
  12. doi Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca/ts phenotype
    Chengjun Mo
    MedImmune Vaccines Inc, 297 N Bernardo Avenue, Mountain View, California, CA 94043, USA
    J Virol Methods 150:63-9. 2008
    ..The Alamar blue dye assay is user friendly, environmentally safe and sensitive. Also, it is adaptable to automation, which could provide a high-throughput platform for analysis of pre-clinical and clinical samples...
  13. ncbi Development of molecular and cellular biomarkers of pain
    Norman C Peterson
    Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, USA
    Comp Med 57:554-62. 2007
    ....
  14. doi Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial
    Jordana Schmier
    MedImmune Inc in Gaithersburg, Maryland, USA
    Health Aff (Millwood) 27:w96-104. 2008
    ..The results show that immunization reduces disease among children and adults and is cost-saving to society. An epidemiologically based influenza immunization policy might be an important supplement to the existing risk-based policy...
  15. pmc Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years
    Chin Fen Yang
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
    Virol J 6:138. 2009
    ..Human metapneumovirus (HMPV) is an important cause of acute respiratory illness in children. We examined the diversity and molecular evolution of HMPV using 85 full-length F (fusion) gene sequences collected over a 20-year period...
  16. doi Increased vagal airway tone in fatal asthma
    Nestor A Molfino
    MedImmune, LLC, Clinical Development, One MedImmune Way, Office 45C20, Gaithersburg, MD 20854, USA
    Med Hypotheses 74:521-3. 2010
    ..If the airway tone is increased, individuals should be treated with a triple combination of long-acting beta(2) agonists, inhaled steroids, and inhaled anticholinergics to prevent vagally mediated fatal events...
  17. pmc Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
    Claire L Dobson
    MedImmune, Cambridge, Cambridgeshire, UK
    MAbs 1:552-62. 2009
    ..Some of these selected scFv have been converted to IgG format and are being studied extensively in clinical trials to investigate their potential utility as human monoclonal antibody therapeutics for the treatment of human cancer...
  18. doi Attending work while sick: implication of flexible sick leave policies
    Matthew D Rousculp
    Health Outcomes and Pharmacoeconomics, MedImmune, LLC, Gaithersburg, MD 20878, USA
    J Occup Environ Med 52:1009-13. 2010
    ..To examine the impact of various flexible sick leave policies (FSLPs) on workplace attendance of employees with self-reported "severe" influenza-like-illness (ILI) symptoms...
  19. pmc TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein
    Deborah L Clarke
    Nottingham Respiratory Biomedical Research Unit, City Hospital, University of Nottingham, Nottingham NG5 1PB, United Kingdom
    J Biol Chem 285:29101-10. 2010
    ....
  20. ncbi Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection
    Taff Jones
    MedImmune, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    Curr Opin Investig Drugs 11:964-70. 2010
    ..If Vacc-4x vaccinees demonstrate significantly better responses than the placebo group in this trial, the prospects for Vacc-4x could be highly promising...
  21. doi Integrated mimicry of B cell antibody mutagenesis using yeast homologous recombination
    Jeffrey S Swers
    Department of Chemical Engineering, Massachusetts Institute of Technology, Building E19 551, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Mol Biotechnol 47:57-69. 2011
    ....
  22. pmc Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis
    Lynne A Murray
    Promedior, Inc, 371 Phoenixville Pike, Malvern, PA, 19355, USA
    Fibrogenesis Tissue Repair 3:11. 2010
    ..To evaluate the effect of the anti-fibrotic protein serum amyloid P (SAP) on radiation-induced oral mucositis (OM) and fibrosis in a hamster cheek-pouch model...
  23. doi SEDVIEW, real-time sedimentation analysis
    David B Hayes
    MedImmune, Inc, Analytical Biochemistry, Gaithersburg, MD 20878, USA
    Macromol Biosci 10:731-5. 2010
    ..A software package called SEDVIEW has been developed by us to allow early analysis in real-time...
  24. doi Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process
    Meena George
    Cell Culture Development, MedImmune, 3055 Patrick Henry Dr, Santa Clara, California 95054, USA
    Biotechnol Bioeng 106:906-17. 2010
    ....
  25. pmc Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion
    Kelly Huang
    MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    J Virol 84:8132-40. 2010
    ..Based on models developed from numerous studies of viral fusion proteins, our results indicate that these antibodies may prevent conformational changes in F protein required for the fusion process...
  26. doi MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
    Roland Kolbeck
    Department of Respiratory, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD 20878, USA
    J Allergy Clin Immunol 125:1344-1353.e2. 2010
    ....
  27. doi The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response
    Zhongying Chen
    MedImmune, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    Vaccine 28:4079-85. 2010
    ..Our results demonstrated the importance of careful evaluation of vaccine strains to ensure that the selected vaccines not only replicate well in eggs, but also retain their antigenicity and are immunogenic in the host...
  28. pmc Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages
    Lynne A Murray
    Promedior, Inc, Malvern, Pennsylvania, United States of America
    PLoS ONE 5:e9683. 2010
    ..These data highlight the role of macrophages in fibrotic lung disease, and demonstrate a therapeutic action of SAP on macrophages which may extend to many fibrotic indications caused by over-exuberant pro-fibrotic macrophage responses...
  29. doi A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children
    Wei Zhu
    MedImmune, Translational Sciences, Gaithersburg, MD 20878, USA
    Vaccine 28:2865-76. 2010
    ....
  30. doi Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing
    Kelly Huang
    MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    Virus Genes 40:212-21. 2010
    ....
  31. ncbi Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets
    H Jin
    MedImmune, Inc, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    Vaccine 25:8664-72. 2007
    ..Thus, smaller vaccine dose volumes should be considered for evaluation of LAIV in animal models...
  32. ncbi Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab
    H Wu
    MedImmune, Inc, One MedImmune Way, Gaithersburg, MD 20878, USA
    Curr Top Microbiol Immunol 317:103-23. 2008
    ..The development of these anti-RSV approaches exemplifies the accelerated pace of drug development made possible with cutting-edge antibody engineering technologies...
  33. ncbi Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys
    Christine M Bachy
    Department of Molecular Biology and Biochemistry, MedImmune, Inc, Gaithersburg, MD 20878, USA
    Oncology 67:187-93. 2004
    ..These studies strengthen the argument for subcutaneous administration of amifostine in radiation oncology...
  34. pmc Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys
    Roderick S Tang
    MedImmune Vaccines Inc, 297 N Bernerdo Avenue, Mountain View, CA 94043, USA
    J Virol 78:11198-207. 2004
    ..The PIV3-vectored RSV vaccines evaluated here further underscore the utility of this vector system for developing safe and immunogenic pediatric respiratory virus vaccines...
  35. ncbi Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model
    David R Cassatt
    Department of Molecular Biology Biochemistry, MedImmune, Inc, Gaithersburg, MD 20872, USA
    Int J Radiat Oncol Biol Phys 57:794-802. 2003
    ..To determine whether SC administration was equivalent to IV administration, we used models to follow pharmacokinetics and oral mucosal protection in rats...
  36. ncbi Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV
    Aurelia A Haller
    MedImmune Vaccines Inc, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    J Gen Virol 84:2153-62. 2003
    ..Such a vaccine would vastly reduce the respiratory disease burden, the associated hospitalization costs and, most importantly, decrease morbidity and mortality of infants, immunocompromised individuals and the elderly...
  37. ncbi Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer
    Michael S Kinch
    MedImmune, Inc, Gaithersburg, Maryland 20878, USA
    Clin Exp Metastasis 20:59-68. 2003
    ..We also show that differential EphA2 expression and function may provide a unique opportunity for selective therapeutic targeting of EphA2 in metastatic disease...
  38. ncbi B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals
    Genevieve A Losonsky
    Department of Pediatrics, Baltimore, MD 21201, USA
    Vaccine 21:562-5. 2003
    ..01 and P=0.05, respectively). These results provide the first evidence that specific gastric B cell responses can be induced in HP-non-infected individuals following oral immunization...
  39. ncbi Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences
    William F Dall'Acqua
    MedImmune, Gaithersburg, MD 20878, USA
    J Immunol 169:5171-80. 2002
    ..We propose that higher affinity to FcRn at pH 7.4 adversely affects release into the serum and offsets the benefit of the enhanced binding at pH 6.0...
  40. pmc Rescue of influenza B virus from eight plasmids
    Erich Hoffmann
    MedImmune Vaccines, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    Proc Natl Acad Sci U S A 99:11411-6. 2002
    ..Our results demonstrate that the eight-plasmid system can be used for the generation of high yields of influenza B virus vaccines expressing current HA and NA glycoproteins from either of the two lineages of influenza B virus...
  41. ncbi Multicenter US study of hospital resource utilization associated with cytomegalovirus-related readmission of renal and heart transplant patients
    R Henderson
    MedImmune, Inc, Gaithersburg, Maryland 20878, USA
    Transpl Infect Dis 3:57-9. 2001
    ..9 days (range 2-95). CMV-related hospital resource use represented a significant portion of the average cost of the original transplant and associated length of stay...
  42. ncbi A method for identifying the financial burden of hospitalized infants on families
    Shelah Leader
    MedImmune Inc, 35 West Watkins Mill Road, Gaithersburg, MD 20878, USA
    Value Health 5:55-9. 2002
    ..To describe a method for measuring the direct and indirect costs to families of infants hospitalized with respiratory syncytial virus (RSV)...
  43. ncbi Malaria vaccines: triumphs or tribulations?
    W R Ballou
    Department of Immunology, Walter Reed Army Institute of Research, Washington, DC 20307 5100, USA
    Parassitologia 41:403-8. 1999
    ..It describes recent encouraging results in human subjects with the RTS,S vaccine, a promising pre-erythrocytic malaria vaccine candidate...
  44. ncbi A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9
    S Johnson
    MedImmune, Inc, Gaithersburg, MD 20878, USA
    J Infect Dis 180:35-40. 1999
    ..The enhanced activity of MEDI-493 compared with RSHZ19 may, in part, explain its better clinical effect...
  45. pmc Characterization of a major neutralizing epitope on human papillomavirus type 16 L1
    W I White
    MedImmune, Inc, Gaithersburg, Maryland 20878, USA
    J Virol 73:4882-9. 1999
    ..V5 epitope was restored, elicited HPV-16 antibody responses comparable to those obtained with 114K VLPs. These results demonstrate the importance of the H16.V5 epitope in the generation of potent HPV-16 neutralizing antibody responses...
  46. ncbi Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA
    Stanley R Pillemer
    Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA
    J Rheumatol 32:143-9. 2005
  47. ncbi Developing new infectivity assays
    D N Galbraith
    BioReliance, West of Scotland Science Park, Glasgow, UK
    Dev Biol (Basel) 118:47-53. 2004
  48. ncbi A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys
    Roderick S Tang
    MedImmune Vaccines Inc, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    Vaccine 23:1657-67. 2005
    ..These studies showed that b/h PIV3/hMPV F2 was immunogenic, protective and attenuated in non-human primates and warrants further evaluation in humans as a vaccine candidate for prevention of hMPV-associated respiratory tract diseases...
  49. ncbi A case of human T lymphotropic virus type I-associated synovial swelling
    Gregory Dennis
    Clinical Development for Inflammatory Diseases at MedImmune, Inc, MD, USA
    Nat Clin Pract Rheumatol 3:675-80. 2007
    ..Consequently, obtaining synovial tissue for analyses is likely to be helpful in determining which process is causing the clinical symptoms...
  50. pmc Cloning of the canine RNA polymerase I promoter and establishment of reverse genetics for influenza A and B in MDCK cells
    Zhaoti Wang
    MedImmune, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    Virol J 4:102. 2007
    ..The objective of this study was to develop a highly efficient method for direct rescue of influenza virus in MDCK cells...
  51. ncbi Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct
    Scott A Hammond
    MedImmune, Inc, Gaithersburg, Maryland 20878, USA
    Cancer Res 67:3927-35. 2007
    ....
  52. ncbi Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies
    Rakesh Dixit
    Toxicology Translational Sciences, MedImune Inc, 1 MedImmuneway, Gaithersburg, MD 20878, USA
    Drug Discov Today 12:336-42. 2007
    ..Therefore, we suggest that, where appropriate, new animal models of human disease (s) are introduced into drug safety assessment...
  53. ncbi Implementing glucose control protocols in critically ill patients
    Gregory M Susla
    Medical Information, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    AACN Adv Crit Care 18:5-9. 2007
  54. ncbi Economic burden and absenteeism from influenza-like illness in healthy households with children (5-17 years) in the US
    Su Li
    PharmacoEconomics and Outcomes Research Group, Medical Affairs, MedImmune Inc, One MedImmune Way, Gaithersburg, MD 20878, USA
    Respir Med 101:1244-50. 2007
    ..School children (5-17 years) function as vectors in influenza epidemics. The objective of this study was to quantify the burden of influenza-like illness (ILI) on US healthy households with school-aged children...
  55. ncbi Modulation of the effector functions of a human IgG1 through engineering of its hinge region
    William F Dall'Acqua
    Department of Antibody Discovery and Protein Engineering, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA
    J Immunol 177:1129-38. 2006
    ..We also define, for the first time in such a systematic fashion, the relationship between various characteristics of the middle and upper hinge and the corresponding effector functions...
  56. ncbi Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs
    Bin Lu
    MedImmune Vaccines, Inc, 297N Bernardo Avenue, Mountain View, CA 94043, USA
    Vaccine 24:6691-3. 2006
    ..We showed that a single amino acid substitution of either G186V or A196T in the HA resulted in significantly increased virus replication in eggs without affecting virus antigenicity...
  57. ncbi Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
    William F Dall'Acqua
    Department of Antibody Discovery and Protein Engineering, MedImmune, Inc, Gaithersburg, Maryland 20878, USA
    J Biol Chem 281:23514-24. 2006
    ..Therefore, the YTE substitutions allow the simultaneous modulation of serum half-life, tissue distribution and activity of a given human IgG1...
  58. ncbi Characterization of the effects of Bcl-2 and Bcl-xl deletion mutant expression in cell lines used for antibody production
    Norman C Peterson
    Department of Comparative Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Hybridoma (Larchmt) 24:275-82. 2005
    ....
  59. ncbi Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization
    Herren Wu
    MedImmune, Inc, One MedImmune Way, Gaithersburg, MD 20878, USA
    J Mol Biol 350:126-44. 2005
    ..These anti-RSV antibodies likely will offer great clinical potential for RSV immunoprophylaxis. In addition, our findings provide insights into engineering potent antibody therapeutics for other disease targets...
  60. ncbi Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift from A/Panama/2007/99
    Hong Jin
    MedImmune Vaccines, Inc, 297 North Bernardo Avenue, Mountain View, CA 94043, USA
    Virology 336:113-9. 2005
    ....
  61. ncbi Tailor-made antibody therapeutics
    Partha S Chowdhury
    Department of Antibody Discovery and Protein Engineering, MedImmune, Inc, One MedImmune Way, Gaithersburg, MD 20878, USA
    Methods 36:11-24. 2005
    ..Described in this review is an abridged account of the different ways antibodies have been tailored to make them efficient drug molecules...
  62. pmc Identification and characterization of SirA, an iron-regulated protein from Staphylococcus aureus
    J H Heinrichs
    MedImmune, Inc, Gaithersburg, Maryland 20878, USA
    J Bacteriol 181:1436-43. 1999
    ..aureus culture medium. sir-encoded proteins may be involved in iron acquisition in vivo and therefore may be targets for antimicrobial agents...